Debrisoquin sulfate (Ro 5-3307)

sc-200725

Material Safety Data Sheet

Hazard Alert Code Key: EXTREME HIGH MODERATE LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Debrisoquin sulfate (Ro 5-3307)

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY:
ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9573 3112

SYNONYMS
C10-H13-N3.1/2H2SO4, "debrisoquin sulfate", "2(1H)-isoquinolinecarboxamidine, 3, 4-dihydro-, sulfate (2:1)", "3, 4-dihydro-2(1H)-isoquinoline carboxamidine sulfate", "isocaramidine sulfate", "2(1H)-isoquinolinecarboximidamide, 3, 4-dihydro-, sulfate (2:1)", "1, 2, 3, 4-tetrahydroisoquinoline-2-carboximidamide sulfate", Equitoril, Declinax, "Ro 5-3307/1", Ro-533071, Tendor, "peripheral monoamine oxidase inhibitor (MOI)", vasodilator, "antihypertensive quaternary ammonium compound"

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th>Flammability</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body Contact</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reactivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CANADIAN WHMIS SYMBOLS

Min/Nil=0
Low=1
Moderate=2
High=3
Extreme=4
TIQs are structurally related to MPTP. Laboratory findings indicate that TIQs having a benzyl moiety production and oxidative stress; and decreased ATP production. It confers toxicity and neuronal death through complex I inhibition. This has many deleterious consequences, including increased free radical production and oxidative stress; and decreased ATP production. Parkinsonian syndrome. The active metabolite of MPTP, the 1-methyl-4-phenylpyridinium ion (MPP+) is a potent and irreversible neurotoxicity selectively in nigrostriatal dopaminergic neurons.

Mitochondrial dysfunction has long been implicated in the pathogenesis of PD. Evidence first emerged among the environmental factors that might contribute to the pathogenesis of PD. But the toxicity of the simplest TIQ (with no substituent) is weak, in contrast to that of MPTP, which exerts potent and irreversible neurotoxicity selectively in nigrostriatal dopaminergic neurons. Monoamine oxidase inhibitors (MAOIs) cause low blood pressure, dizziness, drowsiness, weakness and tiredness, dry mouth, constipation, other digestive disturbances (including nausea and vomiting) and swelling. Other symptoms include agitation and tremors, sleep disturbance, blurred vision, difficulty urinating, convulsions, skin rash, loss of white blood cells, sexual disturbances and weight gain.

EMERGENCY OVERVIEW

RISK
Harmful if swallowed.
Toxic to aquatic organisms.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
- At sufficiently high doses the material may be neurotoxic (i.e. poisonous to the nervous system).
- Since the first report that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces parkinsonism, various kinds of low-molecular-weight neurotoxins, such as tetrahydroisoquinoline derivatives (TIQ, 1,2,3,4-tetrahydroisoquinoline), have been identified as possible Parkinson's Disease (PD) inducing substances. TIQ derivatives have various kinds of pharmacological effects. Many of these compounds are present in foods, such as fruits, grains, and related products, and some of them have been detected in mammalian brain. Their chemical structures resemble that of the selective dopaminergic neurotoxin MPTP, and it has been suggested that they are among the environmental factors that might contribute to the pathogenesis of PD. But the toxicity of the simplest TIQ (with no substituent) is weak, in contrast to that of MPTP, which exerts potent and irreversible neurotoxicity selectively in nigrostriatal dopaminergic neurons.

INHALED
- The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS

- Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

There is some evidence that inhaling this product is more likely to cause a sensitization reaction in some persons compared to the general population. There is limited evidence that, skin contact with this product is more likely to cause a sensitization reaction in some persons compared to the general population.

Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung.

Chronic administration of unsubstituted tetrahydroisoquinoline (uTIQ) at 20 mg/kg/day for up to 104 days to squirrel monkeys produced motor symptoms similar to parkinsonism even at 7 days after discontinuation of (uTIQ) and the symptoms were greatly alleviated by levodopa treatment. Biochemical analysis of the brains of TIQ-treated monkeys revealed a significant decrease of dopamine concentration and tyrosine hydroxylase (TH) activity in the substantia nigra, and these biochemical changes were not reversed by 7 days after termination of chronic administration of unsubstituted TIQ. The behavioral and biochemical symptoms of the animals were similar to those found in Parkinson's Disease (PD) patients.

Mitochondrial dysfunction has long been implicated in the pathogenesis of PD. Evidence first emerged following the accidental exposure of drug abusers to 1-methyl-4-phenyl-1, 2, 3, 4-tetrahydropyridine (MPTP) an environmental toxin that results in an acute and irreversible parkinsonian syndrome. The active metabolite of MPTP, the 1-methyl-4-phenylpyridinium ion (MPP+) is an inhibitor of complex I of the mitochondrial electron transport chain and a substrate for the dopamine transporter. It therefore accumulates in dopaminergic neurons, where it confers toxicity and neuronal death through complex I inhibition. This has many deleterious consequences, including increased free radical production and oxidative stress; and decreased ATP production.

TIQs are structurally related to MPTP. Laboratory findings indicate that TIQs having a benzyl moiety at the 1-position exerted stronger
cytotoxicity and inhibitory activity towards mitochondrial complex I. Results also suggest that methylation at the 3-position potentiates the activity to inhibit complex I. Aromatisation of the isoquinoline ring also potentiated cytotoxicity. The metabolic pathways of uTIQ is thought to be similar to the pathway of MPTP metabolism to MPP+.

Respiratory sensitization may result in allergic/asthma like responses; from coughing and minor breathing difficulties to bronchitis with wheezing, gasping.

### Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>debrisoquine sulfate</td>
<td>581-88-4</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>

### Section 4 - FIRST AID MEASURES

**SWALLOWED**
- IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. · Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

**EYE**
- If this product comes in contact with the eyes: · Wash out immediately with fresh running water. · Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

**SKIN**
- If skin contact occurs: · Immediately remove all contaminated clothing, including footwear · Flush skin and hair with running water (and soap if available).

**INHALED**
- If dust is inhaled, remove from contaminated area. · Encourage patient to blow nose to ensure clear passage of breathing. · If irritation or discomfort persists seek medical attention.

### NOTES TO PHYSICIAN

- citing from:
  - MARTINDALE: The Extra Pharmacopoeia, 27th Ed.
  - Rapidly absorbed from the gastrointestinal tract. Its metabolism is subject to genetic polymorphism.
  - for intoxication by the congener, guanethidine monosulfate:
    - In overdose the stomach should be emptied by aspiration and lavage.
    - Diarrhoea may be controlled by giving codeine phosphate or anticholinergic agents such as propantheline bromide. Severe hypotension may respond by placing patient in the supine position with the feet raised. The effects of gross overdose may be treated by infusion of plasma or slow intravenous injection of low doses of pressor agents such as angiotensin, noradrenaline or phenylephrine. The patient must be observed for several hours.

### Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour Pressure (mmHG):</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%):</td>
<td>Not available.</td>
</tr>
<tr>
<td>Specific Gravity (water=1):</td>
<td>Not available.</td>
</tr>
<tr>
<td>Lower Explosive Limit (%):</td>
<td>Not available.</td>
</tr>
</tbody>
</table>

**EXTINGUISHING MEDIA**
- Water spray or fog.
- Foam.

**FIRE FIGHTING**
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), nitrogen oxides (NOx), sulfur oxides (SOx), other pyrolysis products typical of burning organic material.
  - May emit poisonous fumes.
  - May emit corrosive fumes.

**FIRE INCOMPATIBILITY**
- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**
- Glasses:
  - Chemical goggles.
Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

MAJOR SPILLS
- Moderate hazard.
- CAUTION: Advise personnel in area.
- Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
- Do NOT cut, drill, grind or weld such containers.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS
- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS
- Store in original containers.
- Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS

<table>
<thead>
<tr>
<th>Source</th>
<th>Material</th>
<th>TWA ppm</th>
<th>TWA mg/m³</th>
<th>STEL ppm</th>
<th>STEL mg/m³</th>
<th>Peak ppm</th>
<th>Peak mg/m³</th>
<th>TWA F/CC</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>US - Oregon Permissible Exposure Limits (Z-3)</td>
<td>debrisoquine sulfate (Inert or Nuisance Dust: Total dust)</td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td>(d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US OSHA Permissible Exposure Levels (PELs) - Table Z3</td>
<td>debrisoquine sulfate (Inert or Nuisance Dust: (d) Respirable fraction)</td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US OSHA Permissible Exposure Levels (PELs) - Table Z3</td>
<td>debrisoquine sulfate (Inert or Nuisance Dust: (d) Total dust)</td>
<td></td>
<td></td>
<td></td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Hawaii Air Contaminant Limits</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated - Total dust)</td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td>Contaminant</td>
<td>Limit (PNOR)</td>
<td>Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------------------------</td>
<td>--------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Hawaii Air Contaminant Limits</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated - Respirable fraction)</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Oregon Permissible Exposure Limits (Z-3)</td>
<td>debrisoquine sulfate (Inert or Nuisance Dust: Respirable fraction)</td>
<td>5 (d)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - California Permissible Exposure Limits for Chemical Contaminants</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated Respirable fraction)</td>
<td>5 (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Tennessee Occupational Exposure Limits - Limits For Air Contaminants</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated Respirable fraction)</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Wyoming Toxic and Hazardous Substances Table Z1 Limits for Air Contaminants</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated (PNOR)(f)- Respirable fraction)</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US - Michigan Exposure Limits for Air Contaminants</td>
<td>debrisoquine sulfate (Particulates not otherwise regulated, Respirable dust)</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada - Prince Edward Island Occupational Exposure Limits</td>
<td>debrisoquine sulfate (Particles (Insoluble or Poorly Soluble) [NOS] Inhalable particles)</td>
<td>10</td>
<td>See Appendix B current TLV/BEI Book</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PERSONAL PROTECTION**

**RESPIRATOR**
Particulate
Consult your EHS staff for recommendations

**EYE**

- When handling very small quantities of the material eye protection may not be required.
- For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
  - Chemical goggles
  - Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
  - Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove.

ENDOELTABLE
contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
- NOTE: The material may produce skin sensitzation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
dexterity
- Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.
- Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.
- Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
  - polychloroprene
  - nitrile rubber
  - butyl rubber
  - fluoroelastomer
  - polyvinyl chloride
- Gloves should be examined for wear and/or degradation constantly.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit.

ENGINEERING CONTROLS
- Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
- HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

---

**Section 9 - PHYSICAL AND CHEMICAL PROPERTIES**

**PHYSICAL PROPERTIES**

<table>
<thead>
<tr>
<th>State</th>
<th>Divided solid</th>
<th>Molecular Weight</th>
<th>448.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting Range (°F)</td>
<td>525.2</td>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not applicable</td>
<td>Solubility in water (g/L)</td>
<td>Miscible</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
<td>pH (1% solution)</td>
<td>Not available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available</td>
<td>pH (as supplied)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available.</td>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
<td>Relative Vapor Density (air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible</td>
<td>Evaporation Rate</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**APPEARANCE**

White, odourless, crystalline powder with bitter taste; mixes with water (1:40).

---

**Section 10 - CHEMICAL STABILITY**

**CONDITIONS CONTRIBUTING TO INSTABILITY**
· Presence of incompatible materials.
· Product is considered stable.

STORAGE INCOMPATIBILITY

Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION

DEBRISOQUINE SULFATE

TOXICITY AND IRRITATION

DEBRISOQUINE SULFATE:

unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>IRRITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (rat) LD50: 610 mg/kg</td>
<td>Nil Reported</td>
</tr>
<tr>
<td>Oral (mouse) LD50: 235 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (mouse) LD50: 132 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous (mouse) LD50: 136 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (mouse) LD50: 31.7 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

Mydriasis, respiratory depression recorded.

Section 12 - ECOLOGICAL INFORMATION

Toxic to aquatic organisms.

Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

D) Puncture containers to prevent re-use and bury at an authorized landfill.
Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.
A Hierarchy of Controls seems to be common - the user should investigate:
· Reduction
· Reuse
· Recycling
· Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.
· Recycle wherever possible.
· Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

debrisoquine sulfate (CAS: 581-88-4) is found on the following regulatory lists;
"US - Hawaii Air Contaminant Limits","US - Oregon Permissible Exposure Limits (Z-3)","US OSHA Permissible Exposure Levels (PELs) - Table Z3"

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE

■ Cumulative effects may result following exposure*.
■ Possible respiratory and skin sensitiser*.
**ND**
Substance CAS Suggested codes debrisoquine sulfate 581-88-4

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Feb-16-2010
Print Date: Nov-30-2010